THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL

Autor:	L. Rigacci, Agostino Antolino, P. L. Zinzani, Samantha Ferrari, L. De Carolis, Monia Capponi, Paolo Falcucci, Alessandro Pulsoni, Eugenio Lucia, A. Ambrosetti, Robert Foa, Francesco Zaja, Natalia Frattarelli, Enrico Tiacci, Edoardo Simonetti, R. Della Seta, Gianluca Gaidano, Giuseppe Visani, Brunangelo Falini
Rok vydání:	2019
Předmět:	Cancer Research BRAF inhibitor business.industry Hematology General Medicine medicine.disease Oncology Relapsed refractory Cancer research Medicine Rituximab Hairy cell leukemia business Vemurafenib medicine.drug
Zdroj:	Hematological Oncology. 37:110-111
ISSN:	0278-0232
DOI:	10.1002/hon.72_2629
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::744a58d2ede9fb2c77fdde557bf1f658 https://doi.org/10.1002/hon.72_2629 Zobrazit plný text záznamu Plný text